Celgene rolls along with another epigenetic preclinical deal featuring a Canadian biotech

In another declaration of its ongoing commitment to dealmaking, Celgene is turning to longtime partners at Triphase Accelerator for its latest preclinical asset.

The area in focus this time? Epigenetics.